Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERADICATE: Darolutamide in High-Risk Prostate Cancer After Surgery
NCT04484818Phase 3Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Mar 2021
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of darolutamide in prostate cancer (PCa), sponsored by ECOG-ACRIN Cancer Research Group. Started Mar 2021; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04484818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04484818.